Comparison of Therapies for Primary Prevention of Esophageal Variceal Bleeding: A Systematic Review and Network Meta-analysis
- PMID: 30125369
- DOI: 10.1002/hep.30220
Comparison of Therapies for Primary Prevention of Esophageal Variceal Bleeding: A Systematic Review and Network Meta-analysis
Abstract
We performed a systematic review with network meta-analysis (NMA) to compare the efficacy of different approaches in primary prevention of esophageal variceal bleeding and overall survival in patients with cirrhosis with large varices. Thirty-two randomized clinical trials (RCTs) with 3,362 adults with cirrhosis with large esophageal varices and no prior history of bleeding, with a minimum of 12 months of follow-up, were included. Nonselective beta-blockers (NSBB), isosorbide-mononitrate (ISMN), carvedilol, and variceal band ligation (VBL), alone or in combination, were compared with each other or placebo. Primary outcomes were reduction of all-cause mortality and prevention of esophageal variceal bleeding. Random-effects NMA was performed and summary estimates were expressed as odds ratio and 95% confidence intervals (OR; CI). Quality of evidence was critically appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach. Moderate quality evidence supports NSBB monotherapy (0.70; 0.49-1.00) or in combination with VBL (0.49; 0.23-1.02) or ISMN (0.44; 0.21-0.93) for decreasing mortality in patients with cirrhosis with large esophageal varices and no prior history of bleeding. Moderate-quality evidence supports carvedilol (0.21; 0.08-0.56) and VBL monotherapy (0.33; 0.19-0.55) or in combination with NSBB (0.34; 0.14-0.86), and low-quality evidence supports NSBB monotherapy (0.64; 0.38-1.07) for primary prevention of variceal bleeding. VBL carries a higher risk of serious adverse events compared with NSBB. Conclusion: NSBB monotherapy may decrease all-cause mortality and the risk of first variceal bleeding in patients with cirrhosis with large esophageal varices. Additionally, NSBB carries a lower risk of serious complications compared with VBL. Therefore, NSBB may be the preferred initial approach for primary prophylaxis of esophageal variceal bleeding.
© 2018 by the American Association for the Study of Liver Diseases.
Comment in
-
Letter to the Editor: Confirmation of the Optimization to Prevent the First Esophageal Variceal Bleeding?Hepatology. 2019 Jul;70(1):442. doi: 10.1002/hep.30344. Hepatology. 2019. PMID: 30393873 No abstract available.
-
Interventions for Primary Prevention of Esophageal Variceal Bleeding.Hepatology. 2019 Apr;69(4):1382-1384. doi: 10.1002/hep.30463. Epub 2019 Mar 4. Hepatology. 2019. PMID: 30561058 No abstract available.
-
Reply.Hepatology. 2019 Jul;70(1):442-443. doi: 10.1002/hep.30648. Hepatology. 2019. PMID: 30963608 No abstract available.
-
Letter to the Editor: Beta-Blockers Are Preferable to Banding Ligation for Primary Prophylaxis of Variceal Bleeding?Hepatology. 2019 Nov;70(5):1876. doi: 10.1002/hep.30856. Hepatology. 2019. PMID: 31297835 No abstract available.
-
Reply.Hepatology. 2019 Nov;70(5):1877. doi: 10.1002/hep.30855. Hepatology. 2019. PMID: 31306502 No abstract available.
Similar articles
-
Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Mar 30;3(3):CD013122. doi: 10.1002/14651858.CD013122.pub2. Cochrane Database Syst Rev. 2021. PMID: 33784794 Free PMC article.
-
Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 6;4(4):CD013121. doi: 10.1002/14651858.CD013121.pub2. Cochrane Database Syst Rev. 2021. PMID: 33822357 Free PMC article.
-
Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 10;4(4):CD013155. doi: 10.1002/14651858.CD013155.pub2. Cochrane Database Syst Rev. 2021. PMID: 33837526 Free PMC article.
-
Comparison of Therapies for Secondary Prophylaxis of Esophageal Variceal Bleeding in Cirrhosis: A Network Meta-analysis of Randomized Controlled Trials.Clin Ther. 2020 Jul;42(7):1246-1275.e3. doi: 10.1016/j.clinthera.2020.04.014. Epub 2020 Jul 2. Clin Ther. 2020. PMID: 32624321
-
Endoscopic injection of cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension.Cochrane Database Syst Rev. 2015 May 12;2015(5):CD010180. doi: 10.1002/14651858.CD010180.pub2. Cochrane Database Syst Rev. 2015. PMID: 25966446 Free PMC article.
Cited by
-
Antibiotics and probiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and a meta-analysis.PLoS One. 2022 Aug 30;17(8):e0273231. doi: 10.1371/journal.pone.0273231. eCollection 2022. PLoS One. 2022. PMID: 36040984 Free PMC article.
-
Prevention in Hepatology.J Pers Med. 2024 Jan 23;14(2):132. doi: 10.3390/jpm14020132. J Pers Med. 2024. PMID: 38392566 Free PMC article. Review.
-
Beta-blockers in cirrhosis: Evidence-based indications and limitations.JHEP Rep. 2019 Dec 20;2(1):100063. doi: 10.1016/j.jhepr.2019.12.001. eCollection 2020 Feb. JHEP Rep. 2019. PMID: 32039404 Free PMC article. Review.
-
CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PORTAL HYPERTENSION.Acta Clin Croat. 2024 Apr;63(1):214-243. doi: 10.20471/acc.2024.63.01.26. Acta Clin Croat. 2024. PMID: 39959335 Free PMC article.
-
Advances in the management of complications from cirrhosis.Gastroenterol Rep (Oxf). 2024 Aug 5;12:goae072. doi: 10.1093/gastro/goae072. eCollection 2024. Gastroenterol Rep (Oxf). 2024. PMID: 39104730 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical